Form 4: Amgen Director Omar Ishrak Reports Acquisition of 719 Shares of Common Stock

Director Omar Ishrak reports acquiring 719 shares of Amgen common stock on May 31, 2024, through the vesting of Restricted Stock Units.

Summary

• On May 31, 2024, Omar Ishrak, a director of Amgen Inc., acquired 719 shares of Amgen's common stock.
• The acquisition was a result of the vesting of Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
• The price of the acquired shares was $0.
• Following the transaction, Ishrak's beneficial ownership of Amgen common stock increased to 4,695.6673 shares, which includes 134 Dividend Equivalents (DEs).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company director.

Key Dates